Ardelyx, Inc. - Common Stock (ARDX)
3.1300
+0.1200 (3.99%)
NASDAQ · Last Trade: Nov 11th, 5:25 PM EST
Detailed Quote
| Previous Close | 3.010 |
|---|---|
| Open | 3.040 |
| Bid | 3.080 |
| Ask | 3.130 |
| Day's Range | 2.950 - 3.150 |
| 52 Week Range | 2.800 - 8.400 |
| Volume | 3,292,458 |
| Market Cap | 322.76M |
| PE Ratio (TTM) | -13.61 |
| EPS (TTM) | -0.2 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 5,028,760 |
Chart
About Ardelyx, Inc. - Common Stock (ARDX)
Ardelyx Inc is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and kidney-related diseases. The company is committed to creating targeted treatments that address significant unmet medical needs, leveraging its proprietary platform to discover and advance novel compounds. Ardelyx’s research and development efforts aim to improve the quality of life for patients suffering from conditions such as chronic kidney disease and irritable bowel syndrome, with a focus on delivering effective and safe therapeutic options. Read More
News & Press Releases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 11, 2026
Notice to pension funds, asset managers, and fiduciaries: the lawsuit contends Ardelyx maintained its long-term revenue outlook for XPHOZAH and IBSRELA while payer access barriers were allegedly building, before an 18% single-session repricing of ARDX shares.
By SueWallSt · Via GlobeNewswire · November 10, 2026
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET.
By Ardelyx, Inc. · Via GlobeNewswire · November 10, 2026
Ardelyx (NASDAQ:ARDX) Q3 2026: Breakeven EPS, Revenue Miss, Guidance Heldchartmill.com
Via Chartmill · November 3, 2026
LOS ANGELES, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall, Brown & Schwartz LLP · Via GlobeNewswire · November 9, 2026
Regulatory Compliance Focus: The lawsuit contends Ardelyx assured the market it had confidently addressed a shifting Medicare reimbursement environment for XPHOZAH and IBSRELA, while payer utilization-management requirements were allegedly tightening behind the scenes.
By Levi & Korsinsky, LLP · Via GlobeNewswire · November 9, 2026
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2026 / Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. (NASDAQ:ARDX) that a class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · November 6, 2026
LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall, Brown & Schwartz LLP · Via GlobeNewswire · November 5, 2026
Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established.
Via The Motley Fool · November 4, 2026
Patient awareness push and IBSRELA sales growth both gained momentum this quarter.
Via The Motley Fool · November 4, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · November 4, 2026
Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for dialysis-focused drug XPHOZAH.
President and Chief Executive Officer Mike Raab said the company’s two fir
Via MarketBeat · November 3, 2026
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · November 3, 2026
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · November 3, 2026
After-Hours Stock Movers: Nov. 3 Gainers and Loserschartmill.com
Via Chartmill · November 3, 2026
Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year
By Ardelyx, Inc. · Via GlobeNewswire · November 3, 2026
Time-Sensitive: Allegations focus on Ardelyx's representations that its patient-access strategy was working, while more stringent prior authorization and step edit requirements were allegedly slowing new-patient starts for IBSRELA and XPHOZAH
By SueWallSt · Via GlobeNewswire · November 3, 2026
Trial fully enrolled ahead of schedule
By Ardelyx, Inc. · Via GlobeNewswire · November 3, 2026
LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall, Brown & Schwartz LLP · Via GlobeNewswire · November 2, 2026
Promise vs. Reality: Ardelyx pointed investors toward $1.75 billion in combined peak sales for IBSRELA and XPHOZAH, while the complaint alleges payer utilization-management barriers were already restricting patient access before the Company cut 2026 guidance and withdrew its long-term XPHOZAH target.
By Levi & Korsinsky, LLP · Via GlobeNewswire · November 2, 2026
NEW YORK, Oct. 31, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · October 31, 2026
NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action has been filed against Ardelyx, Inc. (NASDAQ:ARDX) on behalf of purchasers of Ardelyx securities between January 13, 2025 and August 6, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · October 30, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 28, 2026
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · October 27, 2026
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while payer prior authorization and step edit requirements were allegedly restricting IBSRELA and XPHOZAH prescriptions
By SueWallSt · Via GlobeNewswire · October 27, 2026
